Bristol Myers' combo hits a roadblock in PhIII kidney test as the search to rival Keytruda continues
Bristol Myers Squibb has hit a snag in its Phase III trial investigating the company’s Opdivo and Yervoy combo in renal cell carcinoma, or RCC …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
